Causes of sarcopenia and frailty in people taking GLP1RAs
- 14 April 2026
- journal article
- editorial
- Published by Springer Nature in Nature Reviews Endocrinology
- Vol. 22 (7) , 383-384
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Weight loss with GLP-1 medicines does not result in a disproportionate loss of muscle mass or function in obese mice and humansCell Reports Medicine, 2026
- Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trialNature Medicine, 2026
- Glucagon‐like peptide‐1 receptor agonists and muscle strength changes in older adults: Risks beyond muscle mass reductionsBritish Journal of Pharmacology, 2026
- Weight regain after cessation of medication for weight management: systematic review and meta-analysisBMJ, 2026
- Fundamental Body Composition Principles Provide Context for Fat-Free and Skeletal Muscle Loss With GLP-1 RA TreatmentsJournal of the Endocrine Society, 2024
- Frailty is characterized by biomarker patterns reflecting inflammation or muscle catabolism in multi‐morbid patientsJournal of Cachexia, Sarcopenia and Muscle, 2022
- Reported Weight Change in Older Adults and Presence of FrailtyThe Journal of Frailty & Aging, 2020
- BMI and all-cause mortality in older adults: a meta-analysisThe American Journal of Clinical Nutrition, 2014
- Ageing is associated with diminished muscle re‐growth and myogenic precursor cell expansion early after immobility‐induced atrophy in human skeletal muscleThe Journal of Physiology, 2013
- The Loss of Skeletal Muscle Strength, Mass, and Quality in Older Adults: The Health, Aging and Body Composition StudyThe Journals of Gerontology, Series A: Biological Sciences and Medical Sciences, 2006